ArticleClinical research in cardiology : official journal of the German Cardiac Society2023
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Inclisiran-An Assessment of the Consistency Between Randomized Controlled Trials and Real-World Evidence: A Systematic Review.Reviews in cardiovascular medicine · 2026Pooled it
- The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Impact of educational attainment on preventive efforts after myocardial infarction: results of the IPP and NET-IPP trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Trial
- Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Article
- Inclisiran Response in a Patient With Familial Hypercholesterolemia After Suboptimal Response to Evolocumab.JACC. Case reports · 2026Article
- Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis.BMC cardiovascular disorders · 2026Observational
- Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry.Cardiovascular drugs and therapy · 2026 · on this mapObservational
- Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.Lipids in health and disease · 2026 · on this mapArticle
- Real-world efficacy of inclisiran: data from a tertiary lipid clinic.The British journal of cardiology · 2026Article
- Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up.Cardiology and therapy · 2025Article
- Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study.Atherosclerosis plus · 2025Article
- A sex-specific genome-wide association study of blood lipid levels in All of Us.medRxiv : the preprint server for health sciences · 2025Article
- Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk.Atherosclerosis plus · 2025Article
- Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction.Journal of clinical medicine · 2025Article
- Inclisiran: Efficacy in Real World-Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Inadequate Response to PCSK9 Inhibitors.JACC. Case reports · 2025Article
- A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months.Clinical Medicine Insights. Cardiology · 2025Review
- Causal relationship between dyslipidemia and diabetic neuropathy: a mendelian randomization study.Metabolic brain disease · 2024Article
- Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsLow-density lipoprotein cholesterol (LDL-C) is the main therapeutic target in the treatment of hypercholesterolemia. Small interfering RNA (siRNA) inclisiran is a new drug, which targets PCSK9 mRNA in the liver, reducing concentrations of circulating LDL-C. In randomized trials, inclisiran demonstrated a substantial reduction in LDL-C. The German Inclisiran Network (GIN) aims to evaluate LDL-C reductions in a real-world cohort of patients treated with inclisiran in Germany.
methodsPatients who received inclisiran in 14 lipid clinics in Germany for elevated LDL-C levels between February 2021 and July 2022 were included in this analysis. We described baseline characteristics, individual LDL-C changes (%) and side effects in 153 patients 3 months (n = 153) and 9 months (n = 79) after inclisiran administration.
resultsSince all patients were referred to specialized lipid clinics, only one-third were on statin therapy due to statin intolerance. The median LDL-C reduction was 35.5% at 3 months and 26.5% at 9 months. In patients previously treated with PCSK9 antibody (PCSK9-mAb), LDL-C reductions were less effective than in PCSK9-mAb-naïve patients (23.6% vs. 41.1% at 3 months). Concomitant statin treatment was associated with more effective LDL-C lowering. There was a high interindividual variability in LDL-C changes from baseline. Altogether, inclisiran was well-tolerated, and side effects were rare (5.9%).
conclusionIn this real-world patient population referred to German lipid clinics for elevated LDL-C levels, inclisiran demonstrated a high interindividual variability in LDL-C reductions. Further research is warranted to elucidate reasons for the interindividual variability in drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.